ECSP077263A - - Google Patents

Info

Publication number
ECSP077263A
ECSP077263A EC2007007263A ECSP077263A ECSP077263A EC SP077263 A ECSP077263 A EC SP077263A EC 2007007263 A EC2007007263 A EC 2007007263A EC SP077263 A ECSP077263 A EC SP077263A EC SP077263 A ECSP077263 A EC SP077263A
Authority
EC
Ecuador
Prior art keywords
present
provides
pharmaceutical composition
composition
crystalline composition
Prior art date
Application number
EC2007007263A
Other languages
English (en)
Spanish (es)
Inventor
Thomas A Miller
Jeannie Chow Wong
Aaron S Cote
Erik A Dienemann
Kimberly Gallagher
Craig Ikeda
Justin Moser
Pavol Rajniak
Robert A Reed
Cindy Starbuck
Hsien-Hsin Tung
Qingxi Wang
Benjamin Max Cohen
Vincent R Capodanno
Brian Sell
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP077263(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ECSP077263A publication Critical patent/ECSP077263A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EC2007007263A 2005-05-20 2007-02-16 ECSP077263A (OSRAM)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68287505P 2005-05-20 2005-05-20
US69312805P 2005-06-23 2005-06-23

Publications (1)

Publication Number Publication Date
ECSP077263A true ECSP077263A (OSRAM) 2007-04-26

Family

ID=37452585

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007263A ECSP077263A (OSRAM) 2005-05-20 2007-02-16

Country Status (20)

Country Link
US (4) US8093295B2 (OSRAM)
EP (2) EP1853245A2 (OSRAM)
JP (2) JP5264174B2 (OSRAM)
KR (2) KR100884500B1 (OSRAM)
AR (1) AR055953A1 (OSRAM)
AU (3) AU2006249440C1 (OSRAM)
BR (1) BRPI0605893A (OSRAM)
CA (1) CA2580367C (OSRAM)
CR (1) CR8912A (OSRAM)
DO (1) DOP2006000113A (OSRAM)
EC (1) ECSP077263A (OSRAM)
IL (1) IL181070A0 (OSRAM)
MA (1) MA28804B1 (OSRAM)
MX (1) MX2007002047A (OSRAM)
MY (1) MY144613A (OSRAM)
NI (1) NI200700031A (OSRAM)
NZ (2) NZ594669A (OSRAM)
PE (1) PE20061390A1 (OSRAM)
TW (2) TWI415603B (OSRAM)
WO (2) WO2006127319A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI415603B (zh) * 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
AU2009305214B2 (en) * 2008-10-15 2015-06-25 Generics [Uk] Limited Process for the preparation of vorinostat
CA2744458A1 (en) * 2008-11-26 2010-06-03 Generics [Uk] Limited Novel processes and pure polymorphs
JP2012509929A (ja) * 2008-11-26 2012-04-26 ジェネリクス・（ユーケー）・リミテッド 多型
US20110313044A1 (en) * 2010-06-18 2011-12-22 Urquima S.A. Polymorphs of Suberoylanilide Hydroxamic Acid
EP3484470A4 (en) * 2016-07-13 2020-02-26 Technion Research & Development Foundation Limited INHIBITORS OF HISTONE DEACETYLASE 4 CYTOPLASMIC COMPLEX FOR THE TREATMENT OR PREVENTION OF VASCULAR OR VALVULAR CALCIFICATION
CN107362148B (zh) * 2017-07-27 2020-04-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用
CA3149796A1 (en) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Anti-cancer agents for the treatment of canine cancers

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5055608A (en) * 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5608108A (en) * 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5175191A (en) * 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
USRE38506E1 (en) * 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
JP3170069B2 (ja) * 1992-10-06 2001-05-28 日水製薬株式会社 徐放性顆粒剤
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
EP1123309A2 (en) 1998-10-13 2001-08-16 Fujisawa Pharmaceutical Co., Ltd. Cyclic tetrapeptides and their use as histone deacetylase inhibitor
JP2003500052A (ja) 1999-05-03 2003-01-07 メチルジーン インコーポレイテッド ヒストン脱アセチル酵素の抑制
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
TR200201052T2 (tr) 1999-09-08 2003-01-21 Sloan-Kettering Institute For Cancer Research Yeni hücre farklılaştırıcı ajanlar sınıfı ve hıstone deacetylase inhibitörleri, ve burada kullanım yöntemleri
EP1748046A3 (en) 1999-11-23 2007-08-22 Methylgene, Inc. Inhibitors of histone deacetylase
DE60143520D1 (de) 2000-03-24 2011-01-05 Methylgene Inc Inhibitoren der histon-deacetylase
AU2001285042A1 (en) 2000-08-18 2002-03-04 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AU2001290131B2 (en) 2000-09-29 2007-11-15 Topotarget Uk Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
WO2002055017A2 (en) 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US7199227B2 (en) * 2001-06-14 2007-04-03 Bristol-Myers Squibb Company Polynucleotides encoding human histone deacetylase HDAC9c
AU2002340253C1 (en) * 2001-10-16 2011-03-31 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US20040132643A1 (en) * 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
JP2005525345A (ja) * 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｔｒｘ媒介性疾患を処置する方法
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
CA2632078C (en) 2002-03-04 2012-08-14 Sloan-Kettering Institute For Cancer Research Methods of inducing terminal differentiation
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
MXPA04010199A (es) * 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Terapia en combinacion para el tratamiento de cancer.
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
AU2003291097A1 (en) * 2002-11-20 2004-06-15 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
EP1613592A4 (en) * 2003-04-01 2008-03-12 Sloan Kettering Inst Cancer HYDROXAMIC ACID COMPOUNDS AND METHODS OF USE THEREOF
RU2356547C2 (ru) * 2003-08-26 2009-05-27 Мерк ЭйчДиЭйСи Рисерч ЛЛС Способы лечения рака с использованием ингибиторов hdac
TWI415603B (zh) * 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
US20090227674A1 (en) 2005-08-18 2009-09-10 Richon Victoria M Combination methods fo saha and targretin for treating cancer
AU2006311808A1 (en) 2005-11-04 2007-05-18 Merck Sharp & Dohme Corp. Methods of using SAHA and bortezomib for treating cancer
CA2626679C (en) 2005-11-04 2011-08-16 Merck & Co., Inc. Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies
US20070197568A1 (en) * 2005-11-04 2007-08-23 Paul Bunn Methods of using SAHA and Erlotinib for treating cancer

Also Published As

Publication number Publication date
EP2292221A2 (en) 2011-03-09
WO2006127319A2 (en) 2006-11-30
PE20061390A1 (es) 2007-01-15
US20100112046A1 (en) 2010-05-06
TWI365068B (en) 2012-06-01
US20100113829A1 (en) 2010-05-06
AU2009201650A1 (en) 2009-05-21
BRPI0605893A (pt) 2007-12-18
IL181070A0 (en) 2007-07-04
MA28804B1 (fr) 2007-08-01
AU2009201650B2 (en) 2011-09-15
NZ553204A (en) 2011-09-30
US20100119596A1 (en) 2010-05-13
EP1853245A2 (en) 2007-11-14
AU2009201652B2 (en) 2011-10-06
KR100993135B1 (ko) 2010-11-10
WO2006127319A3 (en) 2007-03-29
JP2011251985A (ja) 2011-12-15
AU2006249440A1 (en) 2006-11-30
WO2006127321A3 (en) 2007-03-22
US20080132575A1 (en) 2008-06-05
AR055953A1 (es) 2007-09-12
TWI415603B (zh) 2013-11-21
MX2007002047A (es) 2007-04-12
JP2008519081A (ja) 2008-06-05
WO2006127321A2 (en) 2006-11-30
US8093295B2 (en) 2012-01-10
KR20080113135A (ko) 2008-12-26
CR8912A (es) 2008-02-21
KR100884500B1 (ko) 2009-02-20
CA2580367C (en) 2012-08-21
AU2006249440C1 (en) 2009-08-13
MY144613A (en) 2011-10-04
NZ594669A (en) 2013-02-22
EP2292221A3 (en) 2011-08-10
AU2009201652A1 (en) 2009-05-21
AU2006249440B2 (en) 2009-03-12
TW201034660A (en) 2010-10-01
KR20070062505A (ko) 2007-06-15
US8450372B2 (en) 2013-05-28
NI200700031A (es) 2008-03-03
US8288440B2 (en) 2012-10-16
JP5308486B2 (ja) 2013-10-09
TW200727892A (en) 2007-08-01
AU2010201359A1 (en) 2010-04-29
CA2580367A1 (en) 2006-11-30
DOP2006000113A (es) 2006-10-31
JP5264174B2 (ja) 2013-08-14

Similar Documents

Publication Publication Date Title
ECSP077263A (OSRAM)
TN2009000093A1 (en) Pharmaceutical compositions comprising nilotinib or its salt
BRPI0910734A2 (pt) composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo.
CR20110110A (es) Composicion farmaceutica
MX2011012122A (es) Derivados de tiofeno.
CO7310528A2 (es) Composición farmacéutica recubierta que contiene regorafenib
DOP2006000170A (es) Nuevos derivados de espirocromanona
BR112014009031A2 (pt) formulações de etanercept estabilizadas com íons de metais
UY32599A (es) Formulación oral sólida de abt-263
PL2150530T3 (pl) Podstawione pochodne sulfonamidu
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
WO2012168885A3 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
BR112014008783A2 (pt) compostos para o tratamento e profilaxia da doença causada por vírus sincicial respiratório
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
IL192190A0 (en) Process for the preparation of pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid
UA94624C2 (uk) Арипіпразолу геміфумарат і спосіб його одержання
CL2008002781A1 (es) Sal de oxo-zirconio hexamerico-octaglicina; proceso para preparar esta sal; cation de oxo-zirconio hexamerico-octaglicina que comprende clorhidrato de aluminio; metodo para preparar un compuesto antitranspirante que contiene oxo-zirconio hexamerico-octaglicina.
TW200718698A (en) Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
WO2009108017A3 (en) New pyruvate derivatives with neuroprotective effect, process for preparing the same and pharmaceutical composition comprising the same
CY1117873T1 (el) ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ (1r,4r)-6’-ΦΘΟΡΟ-(Ν,Ν-ΔΙΜΕΘΥΛΟ)-4-ΦΑΙΝΥΛΟ-4΄, 9΄-ΔΙΥΔΡΟ-3’Η-ΣΠΕΙΡΟ-[ΚΥΚΛΟΕΞΑΝΟ-1,1 '-ΠΥΡΑΝΟ-[3,4,b]ΙΝΔΟΛ]-4-ΑΜΙΝΗΣ ΚΑΙ ΘΕΙΙΚΟΥ ΟΞΕΟΣ
WO2012153347A3 (en) Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate
WO2011059207A3 (en) Arylpiperazine-containing purine derivatives and uses thereof
WO2013074905A3 (en) Compounds, compositions, pharmaceutical compositions, and methods of use